{"summary":"I provide strategic technical operations and regulatory CMC leadership to develop and commercialize novel therapeutics for clients ranging from virtual start-ups to large pharma. I have successfully led teams in gene-to-clinic programs, late-stage tech transfers, and in authoring CMC sections for various regulatory submissions, including INDs, BLAs, MAAs, and post-approval variations for biologics and combination products.  My more than 20 years of industry experience crosses multiple modalities: small molecules, enzyme replacements, antibodies, fusion proteins, ADCs, plasma-derived, and cell and gene therapies.    \n\nMy working style relies on effective and open communication of strategic objectives, risks, and technical details to inform and motivate engagement across departments, and companies.  Most successes in this industry are shared with multiple collaborators.","lastName":"Mclaughlin","objectUrn":"urn:li:member:39216303","geoRegion":"Concord, Massachusetts, United States","fullName":"Benjamin Mclaughlin","firstName":"Benjamin","currentPositions":[{"companyName":"Amylaza Consulting","description":"Provide clients with strategic Technical Operations and Regulatory CMC leadership to develop and commercialize novel therapeutics.\n\u2022 Lead teams authoring Module 2 and 3 sections for INDs, BLAs, MAAs, and post-approval variations, including additional DS, DP sites, and additional presentations for biologics and combination products mAbs, antibody-drug conjugates, biologics, autologous cell therapies.\n\u2022 Direct strategic sourcing initiatives to identify API, DS, and Drug Product manufacturing sites review contracts, cell line licensing, and quality agreements, and initiate tech transfer or gene-to-clinic development.\n\u2022 Provide key point of contact interface between clients and CDMOs executing gene-to-clinic programs.\n\u2022 Perform CMC, Reg CMC Due-Diligence evaluating development, IND, and late-stage clinical assets.\n\u2022 Develop CMC Questions, represent client CMC Teams at FDA Type C Meetings, and solicit scientific Advice from other health authorities.\n\u2022 Determine Strategy, and manage responses to CMC questions from health agencies in North America, Europe, and the rest of the world, including complete response remediation and strategies to remove clinical hold on first-in-human trials\n\u2022 Redact\/Revise dossiers to address regional requirements in ROW markets, including China, Brazil, GCC, etc.\n\u2022 Support submissions through MAA approvals in EU, China, Russia, Taiwan, Brazil, Saudi Arabia, etc.\n\u2022 Assess manufacturing facilities and tech transfer plans for clinical stage cell therapy products, and validation documents for a lentiviral vector process for CAR-T therapy.\n\u2022 Manage external development and manufacturing for biologics (CHO, E. coli, aspergillus) and small molecules.\n\u2022 Lead CMC tech Operations Activities for accelerated development of a novel-COVID related antibody treatment\n\u2022 Person-in-Plant services during tech transfer, PPQ, engineering, and clinical manufacturing.\n\u2022 Provide engineering procurement support for process-related capital expenses.","title":"Principal Consultant","companyUrnResolutionResult":{"employeeCountRange":"2-10","headquarters":{"geographicArea":"Massachusetts","country":"United States","city":"Acton","postalCode":"01720","line1":"241 Arlington St"},"website":"http:\/\/www.amylaza.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/amylaza\/","industry":"Biotechnology Research"},"companyUrn":"urn:li:fs_salesCompany:28981827","tenureAtCompany":{"numYears":11,"numMonths":5},"startedOn":{"month":1,"year":2013}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAJWZK8BTDN5oCpY92TDjKkHaTfYp6JQc_0,NAME_SEARCH,uX8e)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1693166982158?e=1723075200&v=beta&t=VHMBrvvsg33-HufwaB4nf5JZH3pRQlL9dp4M3NXJEDc","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1693166982158?e=1723075200&v=beta&t=FQjOyNH-GZ5-VoUuTeLZDqV67xM81mxWSlQYWumIXBc","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1693166982158?e=1723075200&v=beta&t=JLsVNeluNuQ4-flOrk1nJK_QNLjif5YTfx8VHxjDGKw","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1693166982158?e=1723075200&v=beta&t=amuZXSdeVWp-zFdKLoxuFfaMCpSpFvYa0EiWnkzsnc8","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E03AQFRr7I31yVl2A\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Biotechnology Research","educations":[{"endedOn":{"year":2003},"degree":"M.S.E","eduId":29171340,"schoolUrn":"urn:li:fs_salesSchool:157330","school":"urn:li:fs_salesSchool:157330","fieldsOfStudy":["Chemical Engineering"],"startedOn":{"year":2002}},{"endedOn":{"year":2002},"degree":"B.S.","eduId":29171352,"schoolUrn":"urn:li:fs_salesSchool:157330","school":"urn:li:fs_salesSchool:157330","fieldsOfStudy":["Chemical Engineering, minor in English"],"startedOn":{"year":1998}}],"skills":[{"numOfEndorsement":0,"name":"Common Technical Document (CTD)"},{"numOfEndorsement":0,"name":"EMA"},{"numOfEndorsement":0,"name":"Project Teams"},{"numOfEndorsement":0,"name":"Negotiation"},{"numOfEndorsement":0,"name":"Leadership"},{"numOfEndorsement":0,"name":"Emotional Intelligence"},{"numOfEndorsement":0,"name":"Conflict Resolution"},{"numOfEndorsement":0,"name":"Regulatory Filings"},{"numOfEndorsement":0,"name":"Clinical Trials"},{"numOfEndorsement":0,"name":"Teamwork"},{"numOfEndorsement":0,"name":"Interpersonal Skills"},{"numOfEndorsement":0,"name":"Strategy"},{"numOfEndorsement":0,"name":"Skill Development"},{"numOfEndorsement":0,"name":"Regulatory Strategy"},{"numOfEndorsement":0,"name":"Pharmaceuticals"},{"numOfEndorsement":0,"name":"New Drug Application (NDA)"},{"numOfEndorsement":0,"name":"Investigational New Drug Application (IND)"},{"numOfEndorsement":0,"name":"Chemistry, Manufacturing, and Controls (CMC)"},{"numOfEndorsement":0,"name":"Biochemistry"},{"numOfEndorsement":0,"name":"Strategic Thinking"},{"numOfEndorsement":0,"name":"Drug Development"},{"numOfEndorsement":0,"name":"Critical Thinking"},{"numOfEndorsement":0,"name":"Regulatory Affairs"},{"numOfEndorsement":0,"name":"Communication"},{"numOfEndorsement":0,"name":"Biochemical Engineering"},{"numOfEndorsement":3,"name":"MS Project"},{"numOfEndorsement":9,"name":"Protein Purification"},{"numOfEndorsement":5,"name":"Regulatory Submissions"},{"numOfEndorsement":1,"name":"Process Development"},{"numOfEndorsement":20,"name":"Technology Transfer"},{"numOfEndorsement":3,"name":"Technical Writing"},{"numOfEndorsement":9,"name":"Validation"},{"numOfEndorsement":2,"name":"Protein Chemistry"},{"numOfEndorsement":2,"name":"Biotechnology"},{"numOfEndorsement":1,"name":"CAPA"},{"numOfEndorsement":3,"name":"Assay Development"},{"numOfEndorsement":3,"name":"R&D"},{"numOfEndorsement":2,"name":"Change Control"},{"numOfEndorsement":7,"name":"FDA"},{"numOfEndorsement":6,"name":"Process Simulation"},{"numOfEndorsement":1,"name":"V&V"},{"numOfEndorsement":12,"name":"GMP"},{"numOfEndorsement":2,"name":"HPLC"},{"numOfEndorsement":2,"name":"Design of Experiments"},{"numOfEndorsement":1,"name":"Quality System"},{"numOfEndorsement":0,"name":"Project Management"},{"numOfEndorsement":1,"name":"U.S. Food and Drug Administration (FDA)"},{"numOfEndorsement":0,"name":"Process Engineering"},{"numOfEndorsement":0,"name":"External Manufacturing"},{"numOfEndorsement":0,"name":"CMC Regulatory Affairs"}],"numOfConnections":752,"patents":[],"headline":"Principal Consultant at Amylaza Consulting","courses":[],"certifications":[],"memberBadges":{"premium":true,"openLink":true,"jobSeeker":true},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/abenmclaughlin","organizations":[],"location":"Concord, Massachusetts, United States","publications":[],"positions":null,"posts":[{"createdAt":1712276820000,"insightId":"446b80dc-dfd0-4679-a736-71d1ee182256","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":9},{"type":"PRAISE","count":1},{"type":"INTEREST","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7181809637715775488","threadUrn":"urn:li:ugcPost:7181809637715775488","reactionsCount":11,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7181809637715775488","message":{"attributes":[],"text":"The podcast transcript is a nice read as well."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"ADC Guidance Snapshot"},"mediaType":"PAGINATEDDOCUMENT"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7181348344080793602","message":{"attributes":[{"length":24,"start":206,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/efi3uK6b"}}},{"length":24,"start":255,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eHgfyCW4"}}},{"length":24,"start":303,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/eyrHadWD"}}}],"text":"FDA published the final guidance for industry, Clinical Pharmacology Considerations for Antibody-Drug Conjugates, and recently published accompaniments to the guidance document:\n\n\ud83d\udd0a Guidance Recap Podcast:\u00a0https:\/\/lnkd.in\/efi3uK6b\n\n\ud83d\udcd8 Podcast Transcript: https:\/\/lnkd.in\/eHgfyCW4\n\n\ud83d\udcd8 Guidance snapshot:\u00a0https:\/\/lnkd.in\/eyrHadWD"},"entityUrn":"urn:li:ugcPost:7181348344080793602"},"entityUrn":"urn:li:ugcPost:7181809637715775488"}}},{"createdAt":1710255960000,"insightId":"b7e2fd4c-7898-4e81-b972-aa86d6c7518c","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":3}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7173333467324227584","threadUrn":"urn:li:ugcPost:7173333467324227584","reactionsCount":3,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7173333467324227584","message":{"attributes":[],"text":"This guidance will provide some peace of mind for sponsors looking to manage minor label changes. "},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"title":{"text":"Draft Guidance: Annual Reportable Labeling Changes..."},"mediaType":"PAGINATEDDOCUMENT"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7173311934564429824","message":{"attributes":[{"start":269,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/egXgZ2kj"}}}],"text":"FDA is announcing a draft guidance which will provide recommendations to holders of approved New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) for nonprescription drug products on documenting minor labeling changes in their next annual report: https:\/\/lnkd.in\/egXgZ2kj"},"entityUrn":"urn:li:ugcPost:7173311934564429824"},"entityUrn":"urn:li:ugcPost:7173333467324227584"}}},{"createdAt":1715958180000,"insightId":"aad68fa8-0ae8-44ef-b54a-f222f3ecec31","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7196927384711766016,7197250411639042048)","threadUrn":"urn:li:ugcPost:7196927384711766016","reactionsCount":0,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congratulation!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7196927384711766016"}}},{"createdAt":1713962040000,"insightId":"6330af1b-75a2-48b5-86fd-ff80c7db3ae6","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7185691051653779456,7188877880431423488)","threadUrn":"urn:li:ugcPost:7185691051653779456","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7185691051653779456"}}},{"createdAt":1713961740000,"insightId":"12a0789f-a740-415e-b544-b43cad5cebb5","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7188334621019754496,7188876679073648641)","threadUrn":"urn:li:ugcPost:7188334621019754496","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations!  I'm sure you'll be an asset to their team."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7188334621019754496"}}},{"createdAt":1712852520000,"insightId":"b03117b0-0444-42a8-9e5b-8fd4dc648d02","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7184221370698874881,7184224233219055616)","threadUrn":"urn:li:activity:7184221370698874881","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7184221370698874881"}}},{"createdAt":1712692140000,"insightId":"7db678af-111a-4e7c-be42-5650a00fd699","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7183099568694120448,7183551624299040768)","threadUrn":"urn:li:activity:7183099568694120448","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations.  I love following this story."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7183099568694120448"}}},{"createdAt":1712690460000,"insightId":"e9d66e9b-368c-4ca0-b09f-e6c294a573fa","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7183095725298192386,7183544557718929408)","threadUrn":"urn:li:activity:7183095725298192386","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7183095725298192386"}}},{"createdAt":1712268000000,"insightId":"95eb7419-ccff-4816-bea8-96f3ed2a155a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7181665842433007617,7181772570189271041)","threadUrn":"urn:li:ugcPost:7181665842433007617","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7181665842433007617"}}},{"createdAt":1711375740000,"insightId":"a75867aa-e48c-4590-8541-9f500b2d1565","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7177059818380120064,7178030295659536386)","threadUrn":"urn:li:ugcPost:7177059818380120064","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations.  This is awesome news."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7177059818380120064"}}}]}